NewAmsterdam Pharma Company NV Profit Margin

The latest profit margin for NAMS is -3644.21% as of June 2026. That compares with -232.9% in the prior-year period — down 1464.7% year over year. That is below the sector sector average of 19.61%. Investors often review this figure alongside NewAmsterdam Pharma Company NV's historical trend and sector peers before judging valuation or financial health.

Over the past year, NAMS's profit margin moved from -232.9% to -3644.21% — a 1464.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NewAmsterdam Pharma Company NV's valuation or profitability profile.

Against its sector companies, NAMS currently prints -3644.21% for profit margin, while the sector average sits near 19.61%. That is roughly 18686.6% below the sector mean. Large gaps often invite a closer look at NewAmsterdam Pharma Company NV's growth, margins, and balance sheet.

Profit Margin shows how effectively NewAmsterdam Pharma Company NV converts resources into returns. At -3644.21%, NAMS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -232.9% in the prior-year period — down 1464.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NAMS's profit margin (-3644.21%), review year-over-year change from -232.9%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.